EUVIMEDEUVIMED entdecken
Crossref

Integrating real‐world data in cost‐effectiveness analysis of universal HLA‐B*15:02 screening in Malaysia

Huey Yi Chong iD, Kheng-Seang Lim iD, Si-Lei Fong iD, Fatiha Hana Shabaruddin iD, Maznah Dahlui iD, Pauline Siew Mei Lai iD, Ching-Ching Ng iD, Nathorn Chaiyakunapruk iD

British Journal of Clinical Pharmacology · 2023-11 · 89 (11) · 3340-3351

DOI: 10.1111/bcp.15818 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 12.07.2023. Verfasst von Huey Yi Chong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cedar Healthcare Technology Research Centre, Cardiff and Vale University Health Board, Cardiff, UK. Hauptthemen laut MEDLINE: Cost-Effectiveness Analysis, Stevens-Johnson Syndrome. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Despite the availability of newer antiseizure medications, carbamazepine (CBZ) remains the gold standard. However, patients of Asian ancestry are susceptible to CBZ‐related severe cutaneous adverse reactions. Universal HLA‐B*15:02 screening is a promising intervention to address this. With the increasing recognition of integrating real‐world evidence in economic evaluations, the cost‐effectiveness of universal HLA‐B*15:02 screening was assessed using available real‐world data in Malaysia.

Methods

A hybrid model of a decision tree and Markov model was developed to evaluate 3 strategies for treating newly diagnosed epilepsy among adults: (i) CBZ initiation without HLA‐B*15:02 screening (current practice); (ii) universal HLA‐B*15:02 screening prior to CBZ initiation; and (iii) alternative prescribing without HLA‐B*15:02 screening. The model was populated with real‐world inputs derived from the Malaysian population. From a societal perspective, base‐case analysis and sensitivity analyses estimated the costs and outcomes over a lifetime. Incremental cost‐effectiveness ratios were calculated.

Results

In the base‐cases analysis, universal HLA‐B*15:02 screening yielded the lowest total costs and the highest total quality‐adjusted life years (QALYs) gained. Compared with current practice, universal screening was less costly by USD100 and more effective by QALYs increase of 0.1306, while alternative prescribing resulted in 0.1383 QALYs loss at additional costs of USD332. The highest seizure remission rate (56%) was estimated for universal HLA‐B*15:02 screening vs . current practice (54%) and alternative prescribing (48%).

Conclusion

Our study suggests that universal HLA‐B*15:02 screening is a cost‐effective intervention in Malaysia. With the demonstrated value of real‐world evidence in economic evaluations, more relevant standardization efforts should be emphasized to better inform decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Effectiveness AnalysisStevens-Johnson SyndromeAdultBenzodiazepinesCost-Benefit AnalysisCarbamazepineHLA-B AntigensHumansHLA-B15 AntigenMalaysiaSoutheast Asian People

Stichwörter der Autor:innen

HLA-B*15:02Stevens-Johnson syndromecost-effectivenessreal-world evidenceseizuretoxic epidermal necrolysis

Substanzen

BenzodiazepinesCarbamazepineHLA-B AntigensHLA-B15 Antigen

Autor:innen und Institutionen

  • Cedar Healthcare Technology Research Centre, Cardiff and Vale University Health Board, Cardiff, UK.
  • Division of Neurology, Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
  • Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia.
  • Health Economic Research and Case-mix Division, Department of Research Development and Innovation, University Malaya Medical Centre, Kuala Lumpur, Malaysia.
  • Department of Primary Care Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
  • Genetics and Molecular Biology Unit, Institute of Biological Sciences, Faculty of Science, Universiti Malaya, Kuala Lumpur, Malaysia.

ORCID-Profile: Huey Yi Chong, Kheng-Seang Lim, Si-Lei Fong, Fatiha Hana Shabaruddin, Maznah Dahlui, Pauline Siew Mei Lai, Ching-Ching Ng, Nathorn Chaiyakunapruk

Zitieren

APA

Chong, H. Y., Lim, K. S., Fong, S. L., Shabaruddin, F. H., Dahlui, M., Mei Lai, P. S., Ng, C. C., & Chaiyakunapruk, N. (2023). Integrating real‐world data in cost‐effectiveness analysis of universal HLA‐B*15:02 screening in Malaysia. British Journal of Clinical Pharmacology, 89(11), 3340-3351. https://doi.org/10.1111/bcp.15818

Vancouver

Chong HY, Lim KS, Fong SL, Shabaruddin FH, Dahlui M, Mei Lai PS, et al. Integrating real‐world data in cost‐effectiveness analysis of universal HLA‐B*15:02 screening in Malaysia. British Journal of Clinical Pharmacology. 2023;89(11):3340-3351. doi:10.1111/bcp.15818

BibTeX
@article{Chong2023,
  author = {Chong, Huey Yi and Lim, Kheng-Seang and Fong, Si-Lei and Shabaruddin, Fatiha Hana and Dahlui, Maznah and Mei Lai, Pauline Siew and Ng, Ching-Ching and Chaiyakunapruk, Nathorn},
  title = {Integrating real‐world data in cost‐effectiveness analysis of universal HLA‐B*15:02 screening in Malaysia},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  volume = {89},
  number = {11},
  pages = {3340--3351},
  doi = {10.1111/bcp.15818}
}
Kostenlos starten →